Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gastaut H: Clinical and electroencephalographical classification of epileptic seizures. Epilepsia. 1970, 11: 102-113. 10.1111/j.1528-1157.1970.tb03871.x.
Vezzani A, French J, Bartfai T, Baram TZ: The role of inflammation in epilepsy. Nat Rev Neurol. 2011, 7: 31-40. 10.1038/nrneurol.2010.178.
Dube C, Vezzani A, Behrens M, Bartfai T, Baram TZ: Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol. 2005, 57: 152-155. 10.1002/ana.20358.
Vezzani A, Friedman A, Dingledine RJ: The role of inflammation in epileptogenesis. Neuropharmacology. 2013, 69: 16-24. 10.1016/j.neuropharm.2012.04.004.
Vezzani A, Baram TZ: New roles for interleukin-1 Beta in the mechanisms of epilepsy. Epilepsy Curr. 2007, 7: 45-50. 10.1111/j.1535-7511.2007.00165.x.
Gomez CD, Buijs RM, Sitges M: The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1beta and TNF-alpha expression in rat hippocampus. J Neurochem. 2014, 130: 770-779. 10.1111/jnc.12784.
Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C: Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A. 2010, 107: 9795-9800. 10.1073/pnas.0914414107.
Maroso M, Balosso S, Ravizza T, Iori V, Wright CI, French J, Vezzani A: Interleukin-1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. 2011, 8: 304-315. 10.1007/s13311-011-0039-z.
Ravizza T, Lucas SM, Balosso S, Bernardino L, Ku G, Noe F, Malva J, Randle JC, Allan S, Vezzani A: Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia. 2006, 47: 1160-1168. 10.1111/j.1528-1167.2006.00590.x.
Haneklaus M, O'Neill LA, Coll RC: Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol. 2013, 25: 40-45. 10.1016/j.coi.2012.12.004.
Cassel SL, Sutterwala FS: Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol. 2010, 40: 607-611. 10.1002/eji.200940207.
Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, Hornung V, Latz E: Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009, 183: 787-791. 10.4049/jimmunol.0901363.
Liu HD, Li W, Chen ZR, Hu YC, Zhang DD, Shen W, Zhou ML, Zhu L, Hang CH: Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem Res. 2013, 38: 2072-2083. 10.1007/s11064-013-1115-z.
Ransohoff RM, Brown MA: Innate immunity in the central nervous system. J Clin Invest. 2012, 122: 1164-1171. 10.1172/JCI58644.
Jha S, Srivastava SY, Brickey WJ, Iocca H, Toews A, Morrison JP, Chen VS, Gris D, Matsushima GK, Ting JP: The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci. 2010, 30: 15811-15820. 10.1523/JNEUROSCI.4088-10.2010.
Rajamaki K, Nordstrom T, Nurmi K, Akerman KE, Kovanen PT, Oorni K, Eklund KK: Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J Biol Chem. 2013, 288: 13410-13419. 10.1074/jbc.M112.426254.
Fann DY, Lee SY, Manzanero S, Chunduri P, Sobey CG, Arumugam TV: Pathogenesis of acute stroke and the role of inflammasomes. Ageing Res Rev. 2013, 12: 941-966. 10.1016/j.arr.2013.09.004.
Wasterlain CG, Fujikawa DG, Penix L, Sankar R: Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia. 1993, 34 (Suppl 1): S37-S53. 10.1111/j.1528-1157.1993.tb05905.x.
Kim JE, Yeo SI, Ryu HJ, Kim MJ, Kim DS, Jo SM, Kang TC: Astroglial loss and edema formation in the rat piriform cortex and hippocampus following pilocarpine-induced status epilepticus. J Comp Neurol. 2010, 518: 4612-4628. 10.1002/cne.22482.
Sheen SH, Kim JE, Ryu HJ, Yang Y, Choi KC, Kang TC: Decrease in dystrophin expression prior to disruption of brain-blood barrier within the rat piriform cortex following status epilepticus. Brain Res. 2011, 1369: 173-183. 10.1016/j.brainres.2010.10.080.
Chen JW, Wasterlain CG: Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006, 5: 246-256. 10.1016/S1474-4422(06)70374-X.
Bjorling DE, Wang Z-Y: Estrogen and neuroinflammation. Urology. 2001, 57: 40-46. 10.1016/S0090-4295(01)01124-4.
Sun Z, Yu JT, Jiang T, Li MM, Tan L, Zhang Q: Genome-wide microRNA profiling of rat hippocampus after status epilepticus induced by amygdala stimulation identifies modulators of neuronal apoptosis. PLoS One 2013, 8:e78375..
Racine RJ: Modification of seizure activity by electrical stimulation. II Motor seizure Electroencephalogr Clin Neurophysiol. 1972, 32: 281-294. 10.1016/0013-4694(72)90177-0.
Thakker DR, Hoyer D, Cryan JF: Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol Ther. 2006, 109: 413-438. 10.1016/j.pharmthera.2005.08.006.
Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, De Simoni MG, Sperk G, Andell-Jonsson S, Lundkvist J, Iverfeldt K, Bartfai T: Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci U S A. 2000, 97: 11534-11539. 10.1073/pnas.190206797.
Marchi N, Fan Q, Ghosh C, Fazio V, Bertolini F, Betto G, Batra A, Carlton E, Najm I, Granata T, Janigro D: Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis. 2009, 33: 171-181. 10.1016/j.nbd.2008.10.002.
Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, Vezzani A: A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain. 2008, 131: 3256-3265. 10.1093/brain/awn271.
Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F, De Simoni MG: Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci. 1999, 19: 5054-5065.
Heida JG, Moshe SL, Pittman QJ: The role of interleukin-1beta in febrile seizures. Brain Dev. 2009, 31: 388-393. 10.1016/j.braindev.2008.11.013.
Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC: Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation. 2000, 7: 153-159. 10.1159/000026433.
Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, Vescovi A, Bagetta G, Kollias G, Meldolesi J, Volterra A: CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci. 2001, 4: 702-710. 10.1038/89490.
Wang S, Cheng Q, Malik S, Yang J: Interleukin-1beta inhibits gamma-aminobutyric acid type A (GABA(A)) receptor current in cultured hippocampal neurons. J Pharmacol Exp Ther. 2000, 292: 497-504.
Loscher W: Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002, 50: 105-123. 10.1016/S0920-1211(02)00073-6.
Vezzani A, Balosso S, Ravizza T: The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun. 2008, 22: 797-803. 10.1016/j.bbi.2008.03.009.
Walsh JG, Muruve DA, Power C: Inflammasomes in the CNS. Nat Rev Neurosci. 2014, 15: 84-97. 10.1038/nrn3638.
Pitkanen A, Sutula TP: Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol. 2002, 1: 173-181. 10.1016/S1474-4422(02)00073-X.
Grant RW, Dixit VD: Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol 2013, 4:50..